Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
2023-508954-25-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Modality
- Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of BMS-986288 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), cutaneous melanoma (CM) and 7 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events (AEs), serious adverse events (SAEs), AEs meeting protocol-defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, death and laboratory… and Objective response rate (ORR) per RECIST v1.1 by blinded independent central review (BICR) (Part 2C). Started May 2022; status: completed.
02
Drugs
BMS-986288
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)cutaneous melanoma (CM)triple-negative breast cancer (TNBC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2023-508954-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508954-25-00.